Who are Alaunos Therapeutics, Inc.'s main suppliers?

Alaunos Therapeutics, Inc. (TCRT) key suppliers include: THE-UNIVERSITY-OF-TEXAS-M-D-ANDERSON-CANCER-CENT, ARES-TRADING-S-A, INTREXON-CORPORATION, NATIONAL-CANCER-INSTITUTE, PGEN-THERAPEUTICS-INC and 2 more. View the full supplier network at chainsifter.com/chain/TCRT.

Who are Alaunos Therapeutics, Inc.'s major customers?

Alaunos Therapeutics, Inc. (TCRT) key customers include: SOLASIA-PHARMA-K-K. View the full customer network at chainsifter.com/chain/TCRT.

What sector is Alaunos Therapeutics, Inc. in?

Alaunos Therapeutics, Inc. (TCRT) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

TCRT Supply Chain: Alaunos Therapeutics, Inc. Supplier List & 10 Relationships

7Suppliers

1Customers

2Debt Items

3Related Chains

Alaunos Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
THE-UNIVERSITY-OF-TEXAS-M-D-ANDERSON-CANCER-CENT	THE-UNIVERSITY-OF-TEXAS-M-D-ANDERSON-CANCER-CENT	92%	Under the Settlement Agreement, the Company agreed to pay MD Anderson a total of $285,055 in full satisfaction of the outstanding invoices
ARES-TRADING-S-A	ARES-TRADING-S-A	90%	10.10† License and Collaboration Agreement by and among the Registrant, Intrexon Corporation and Ares Trading S.A. dated as of March 27, 2015
INTREXON-CORPORATION	INTREXON-CORPORATION	90%	10.6# License Agreement by and among the Registrant, Intrexon Corporation and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as…
NATIONAL-CANCER-INSTITUTE	NATIONAL-CANCER-INSTITUTE	90%	10.18# Patent License Agreement, dated as of May 28, 2019, by and between the Registrant and the National Cancer Institute
PGEN-THERAPEUTICS-INC	PGEN-THERAPEUTICS-INC	90%	10.8# Amendment No. 1 to the Exclusive License Agreement by and between the Registrant and PGEN Therapeutics, Inc. (formerly known as Precigen, Inc.), dated October 15, 2020
PRECIGEN-INC	PRECIGEN-INC	90%	10.7† Exclusive License Agreement by and between the Registrant, Precigen, Inc. and Intrexon Corporation, dated October 5, 2018
THE-UNIVERSITY-OF-TEXAS-SYSTEM-BOARD-OF-REGENTS	THE-UNIVERSITY-OF-TEXAS-SYSTEM-BOARD-OF-REGENTS	90%	10.6# License Agreement by and among the Registrant, Intrexon Corporation and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as…

Alaunos Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
SOLASIA-PHARMA-K-K	SOLASIA-PHARMA-K-K	92%	As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentag…

Alaunos Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
TCRT-DEBT-12917	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2014-12-31.
TCRT-DEBT-12916	Warrants outstanding: 18939394	90%	xbrl warrant detail from xbrl 2026-03-31.

Alaunos Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Alaunos Therapeutics, Inc..

Alaunos Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
TCRT-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC	VANGUARD CAPITAL MANAGEMENT LLC	90%	13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 30 tracked holders.

Alaunos Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
STAB	Statera Biopharma, Inc.	100.00	2
TIVC	Valion Bio, Inc.	36.29	1	['spend']
VBIO	Valion Bio, Inc.	14.78	2

Alaunos Therapeutics, Inc. Supply Chain